DSM-Firmenich AG
DSFIR: XAMS (NLD)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| xYZ | LOCK|YZK | LOCK|brdDW$j |
DSM-Firmenich Earnings: Solid First Half With Good Progress on Innovation and Synergy Realization
DSM-Firmenich reported first-half 2025 organic sales growth of 7% and EBITDA of EUR 1,260 million, 29% higher than the prior year. The results align with the company-compiled consensus, and management confirmed the full-year guidance.
